Visceral Pain Global Market Report 2024

The visceral pain treatment market size has grown strongly in recent years. It will grow from $12.87 billion in 2023 to $13.84 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed in the historical period can be attributed to several factors, including an aging population, an increased incidence of chronic diseases, advancements in medical research, the expansion of healthcare infrastructure, and rising awareness and diagnosis rates.

The visceral pain treatment market size is expected to see strong growth in the next few years. It will grow to $17.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The projected growth in the forecast period is driven by technological innovations in pain management, increasing demand for non-invasive treatment options, the emergence of new markets and untapped opportunities, personalized medicine approaches, and the integration of digital health solutions. Key trends expected during this period include a shift towards multimodal pain management, a growing emphasis on alternative therapies, the rise of targeted therapies tailored to specific types of pain, the expanding role of telemedicine in pain management, and the integration of artificial intelligence in pain assessment.

The anticipated surge in demand for analgesics is poised to drive the expansion of the visceral pain market in the future. Analgesics are medications designed to alleviate pain by reducing or blocking the perception of pain signals in the brain. They play a crucial role in managing visceral pain by targeting the nervous system and modulating pain signals originating from internal organs. For example, as documented by the Centers for Disease Control and Prevention (CDC) in December 2023, there was a notable increase in the total number of dispensed Buprenorphine prescriptions, an opioid analgesic, from 16,011,239 in 2020 to 16,105,318 in 2021, reflecting a significant 0.59% rise compared to the corresponding period in 2020. Consequently, the escalating demand for analgesics serves as a driving force behind the growth of the visceral pain market.

Prominent companies in the visceral pain market are dedicated to developing innovative products such as NHE3 Inhibitors to offer dependable solutions to consumers. NHE3 inhibitors constitute a class of medications that function by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gastrointestinal tract. For example, in April 2022, Ardelyx, a US-based biopharmaceutical firm, introduced an NHE3 Inhibitor medication called IBSRELA. This groundbreaking treatment targets adults with irritable bowel syndrome with constipation (IBS-C), acting on the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. Preclinical studies have demonstrated its efficacy in reducing abdominal pain by alleviating visceral hypersensitivity and intestinal permeability.

In February 2021, Jazz Pharmaceuticals, an Irish pharmaceutical company, completed the acquisition of GW Pharmaceuticals plc for $7.2 billion. Through this strategic move, Jazz Pharmaceuticals is set to expand its offerings with GW's diverse portfolio of cannabinoid products, notably including Epidiolex, the first plant-derived cannabinoid medicine sanctioned by the U.S. FDA. GW Pharmaceuticals plc, based in the US, specializes in the discovery, development, and commercialization of innovative therapeutics primarily targeting chronic visceral pain syndromes.

Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Endo International PLC, Grünenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.,

North America was the largest region in the visceral pain market in 2023. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the visceral pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Visceral pain originates from internal organs such as the stomach, bladder, uterus, or rectum and can stem from factors such as inflammation, menstrual cramps, organ swelling, blockages, reduced blood flow, or tumors, particularly in the pelvis or abdomen, often accompanied by symptoms such as nausea, sweating, or increased heart rate.

The principal drug classes for treating visceral pain include calcium channel blockers (CCBs), nonsteroidal anti-inflammatories (NSAIDs), and others. CCBs regulate calcium ion movement into heart and blood vessel cells, with indications spanning interstitial cystitis, Crohn’s disease, irritable bowel syndrome, chronic prostatitis, and more. These medications are employed across various end-user settings including hospitals, homecare, specialty clinics, among others.

The visceral pain market research report is one of a series of new reports that provides visceral pain market statistics, including visceral pain industry global market size, regional shares, competitors with a visceral pain market share, detailed visceral pain market segments, market trends, and opportunities, and any further data you may need to thrive in the visceral pain industry. This visceral pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The visceral pain market consists of sales of opioids, anticonvulsants, gabapentin, and pregabalin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.